FI96209B - Förfarande för framställning av icke-glykosylerad rekombinant-human-IL2 i dess reducerade form - Google Patents

Förfarande för framställning av icke-glykosylerad rekombinant-human-IL2 i dess reducerade form Download PDF

Info

Publication number
FI96209B
FI96209B FI893587A FI893587A FI96209B FI 96209 B FI96209 B FI 96209B FI 893587 A FI893587 A FI 893587A FI 893587 A FI893587 A FI 893587A FI 96209 B FI96209 B FI 96209B
Authority
FI
Finland
Prior art keywords
leu
thr
glu
ile
asn
Prior art date
Application number
FI893587A
Other languages
English (en)
Finnish (fi)
Other versions
FI893587A (sv
FI96209C (sv
FI893587A0 (sv
Inventor
Danielle Lando
Philippe Riberon
Pierre Yves Abecassis
Original Assignee
Roussel Uclaf
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Roussel Uclaf filed Critical Roussel Uclaf
Publication of FI893587A0 publication Critical patent/FI893587A0/sv
Publication of FI893587A publication Critical patent/FI893587A/sv
Publication of FI96209B publication Critical patent/FI96209B/sv
Application granted granted Critical
Publication of FI96209C publication Critical patent/FI96209C/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/113—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure
    • C07K1/1133—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides without change of the primary structure by redox-reactions involving cystein/cystin side chains
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (3)

1. Förfarande för framställning av ett icke-glyko-sylerat rekombinant-human-interleukin-2, vilket har föl- 5 jande aminosyrasekvens: X-Ala Pro Thr Ser Ser Ser Thr Ly* Ly* Thr Gin Leu Gin Leu Glu Hl» Leu Leu Leu Asp Leu 6ln Het Ile Leu Asn Gly Ile Asn Asn Tyr Ly* Asn Pro Lys Leu Thr Arg Het Leu Thr Phe Ly* Phe Tyr Het Pro Ly* Ly* Ala Thr Glu Leu Lys Hl s Leu Gin Cys Leu Glu Glu Glu Leu Lys Pro Leu Glu Glu Vai Leu Asn Leu Ala Gin Ser Lys Asn Phe H1s Leu Arg Pro Arg Asp Leu Ile Ser Asn Ile Asn Vai Ile Vai Leu Glu Leu Ly* Gly Ser Glu Thr Thr Phe Het Cys Glu Tyr Ala Asp Glu Thr Ala Thr Ile Vai Glu Phe Leu A*n Arg Trp Ile Thr Phe Cys Gin Ser Ile Ile Ser Thr Leu Thr. inklusive alleler och derivat av denna sekvens, i vilken sekvens X är met ionin eller en väteatom och de tre kys-15 teinresterna i ställningar 58, 105 och 125 är i reducerad form, och vilket har en biologisk aktivitet av minst 0,5 x 107 U/mg, i vilket förfarande isoleras IL2, som ackumule-rats i form av granuler i en transformerad mikroorganism, medelst upplösning i ett reducerande medium under använd-20 ning av ett kaotropiskt ämne, varefter det renas medelst utfällning och därefter medelst högtrycksvätskekromatogra-fi med omvänd fas med en sur eluent, känneteck-n a t därav, att: a) om sä önskas, kyls huvudfraktionen, som eluerats 25 i nämnda kromatografiering, tili en temperatur av ca -20 °C, varefter vattenfasen separeras, och b) vattenfasen utspäds med ett surt medium, varefter utförs kromatografiering i en annan högtrycksvätske-kromatografikolonn med omvänd fas genom eluering med en 30 sur lösning och 1L2 isoleras.
2. Förfarande enligt patentkrav 1, känne- t e c k n a t därav, att kylningssteget utförs i en vat-tenlösning av acetonitril, som innehäller ca 0,1 % tri-fluorättiksyra, utspädningen utförs genom användning av en 35 vattenlösning av en organisk syra, säsom citronsyra, och IL2 elueras med en annan kromatografiering genom användning 96209 av en lösning, som innehäller isopropanol, vatten och en organisk syra, säsom citronsyra.
3. Förfarande enligt patentkrav 1 eller 2, k ä n -netecknat därav, att huvudfraktionen ej kyls och 5 vattenfasen ej separeras.
FI893587A 1988-07-28 1989-07-27 Förfarande för framställning av icke-glykosylerad rekombinant-human-IL2 i dess reducerade form FI96209C (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8810184 1988-07-28
FR8810184A FR2635527B1 (fr) 1988-07-28 1988-07-28 Il2 humaine recombinante non glycosylee sous forme reduite, son procede d'obtention et son application comme medicament

Publications (4)

Publication Number Publication Date
FI893587A0 FI893587A0 (sv) 1989-07-27
FI893587A FI893587A (sv) 1990-01-29
FI96209B true FI96209B (sv) 1996-02-15
FI96209C FI96209C (sv) 1996-05-27

Family

ID=9368873

Family Applications (1)

Application Number Title Priority Date Filing Date
FI893587A FI96209C (sv) 1988-07-28 1989-07-27 Förfarande för framställning av icke-glykosylerad rekombinant-human-IL2 i dess reducerade form

Country Status (21)

Country Link
US (2) US5874076A (sv)
EP (1) EP0353150B1 (sv)
JP (1) JP3016793B2 (sv)
KR (1) KR0131070B1 (sv)
CN (1) CN1036532C (sv)
AT (1) ATE110783T1 (sv)
AU (1) AU624625B2 (sv)
DE (1) DE68917826T2 (sv)
DK (1) DK370489A (sv)
ES (1) ES2058573T3 (sv)
FI (1) FI96209C (sv)
FR (1) FR2635527B1 (sv)
HU (1) HU207099B (sv)
IE (1) IE64232B1 (sv)
IL (1) IL90975A (sv)
MX (1) MX16912A (sv)
NZ (1) NZ230111A (sv)
PT (1) PT91295B (sv)
RU (1) RU2105011C1 (sv)
UA (1) UA26846C2 (sv)
ZA (1) ZA895419B (sv)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2660863B1 (fr) * 1990-04-17 1994-01-21 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement de cancers primitifs de la plevre.
FR2668368B1 (fr) * 1990-10-30 1995-03-10 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour preparer une composition pharmaceutique destinee au traitement des tumeurs malignes epitheliales.
WO1992009623A1 (fr) * 1990-11-23 1992-06-11 Roussel-Uclaf PROCEDE DE PREPARATION D'UNE PROTEINE COMPORTANT AU MOINS UN PONT DISULFURE INTRAMOLECULAIRE PAR OXYDATION, A UN pH INFERIEUR A 5,0, DE LA PROTEINE RECOMBINANTE REDUITE CORRESPONDANTE
FR2671728B1 (fr) * 1991-01-17 1995-01-20 Roussel Uclaf Utilisation d'un polypeptide ayant l'activite de l'interleukine 2 humaine pour la preparation de compositions pharmaceutiques destinees au traitement des pneumathorax.
FR2684878B1 (fr) * 1991-12-12 1994-02-11 Roussel Uclaf Composition pharmaceutique stabilisee d'il2 humaine recombinante non glycosylee sous forme reduite et son procede de preparation.
US6470207B1 (en) * 1999-03-23 2002-10-22 Surgical Navigation Technologies, Inc. Navigational guidance via computer-assisted fluoroscopic imaging
US20050203578A1 (en) * 2001-08-15 2005-09-15 Weiner Michael L. Process and apparatus for treating biological organisms
SI2251353T1 (sl) * 2003-08-07 2013-10-30 Zymogenetics, Inc. Homogeni preparati il-29
EP4090674A4 (en) 2020-01-14 2024-01-24 Synthekine Inc METHODS AND COMPOSITIONS OF BIASED IL2 MUTEINS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341562C (en) * 1982-03-31 2007-11-27 Tadatsugu Taniguchi Gene coded for interleukin-2 polypeptide, recombinant dna carrying the said gene, a living cell line possessing the recombinant dna, and method for producing interleukin-2 using the said cell
US5643566A (en) * 1982-09-23 1997-07-01 Cetus Corporation Formulation processes for lipophilic proteins
US4518584A (en) * 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
JPS60115528A (ja) * 1983-11-28 1985-06-22 Takeda Chem Ind Ltd ヒトインタ―ロイキン―２蛋白質を含有する抗腫瘍用または免疫機能低下疾患治療用組成物
US4569790A (en) * 1984-03-28 1986-02-11 Cetus Corporation Process for recovering microbially produced interleukin-2 and purified recombinant interleukin-2 compositions
US4604377A (en) * 1984-03-28 1986-08-05 Cetus Corporation Pharmaceutical compositions of microbially produced interleukin-2
EP0158487B1 (en) * 1984-04-09 1991-08-28 Takeda Chemical Industries, Ltd. Stable composition of interleukin-2
US4654830A (en) * 1984-11-27 1987-03-31 Monolithic Memories, Inc. Method and structure for disabling and replacing defective memory in a PROM
US4690915A (en) * 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
JPH0829113B2 (ja) * 1986-11-11 1996-03-27 武田薬品工業株式会社 ヒトインタ−ロイキン−２の製造法

Also Published As

Publication number Publication date
HU207099B (en) 1993-03-01
HUT51647A (en) 1990-05-28
IE64232B1 (en) 1995-07-26
JPH02209896A (ja) 1990-08-21
US5814314A (en) 1998-09-29
RU2105011C1 (ru) 1998-02-20
IL90975A0 (en) 1990-02-09
EP0353150A1 (fr) 1990-01-31
DK370489A (da) 1990-01-29
CN1042377A (zh) 1990-05-23
IL90975A (en) 1994-11-28
PT91295A (pt) 1990-02-08
UA26846C2 (uk) 1999-12-29
DK370489D0 (da) 1989-07-27
EP0353150B1 (fr) 1994-08-31
FI893587A (sv) 1990-01-29
IE892443L (en) 1990-01-28
JP3016793B2 (ja) 2000-03-06
KR900001854A (ko) 1990-02-27
ZA895419B (en) 1990-09-26
KR0131070B1 (ko) 1998-04-11
ATE110783T1 (de) 1994-09-15
ES2058573T3 (es) 1994-11-01
MX16912A (es) 1993-10-01
US5874076A (en) 1999-02-23
CN1036532C (zh) 1997-11-26
FR2635527B1 (fr) 1992-06-12
PT91295B (pt) 1995-03-01
FR2635527A1 (fr) 1990-02-23
DE68917826T2 (de) 1995-01-12
FI96209C (sv) 1996-05-27
NZ230111A (en) 1992-04-28
AU624625B2 (en) 1992-06-18
FI893587A0 (sv) 1989-07-27
AU3902489A (en) 1990-02-01
DE68917826D1 (de) 1994-10-06

Similar Documents

Publication Publication Date Title
US4604377A (en) Pharmaceutical compositions of microbially produced interleukin-2
US7858082B2 (en) Method of stabilizing proteins
FI95002B (sv) Förfarande för framställning av stabila, farmaceutiska sammansättningar av oglykosylerat rekombinantinterferon-
EP0077670B1 (en) Human immune interferon
JP2961189B2 (ja) ヒトインターロイキン２の活性を有するポリペプチドからなることを特徴とする白血病を治療するための医薬組成物
EP0357645B1 (en) Improved process for recovering microbially produced interleukin-2
EP0211835B1 (en) Pharmaceutical compositions of microbially produced interleukin-2
FI96209B (sv) Förfarande för framställning av icke-glykosylerad rekombinant-human-IL2 i dess reducerade form
US5643566A (en) Formulation processes for lipophilic proteins
Ouellette et al. Production and purification of refolded recombinant human IL-7 from inclusion bodies
US4855409A (en) Novel polypeptides and method of producing same
IE61444B1 (en) Process for preparing and purifying interferon
KR20070030855A (ko) 단백질을 안정화하는 방법
EP0401379B1 (en) STABILIZED COMPOSITION OF INTERLEUKIN-1$g(b)
Geigert et al. Development and shelf-life determination of recombinant interleukin-2 (proleukin)
CA1283356C (en) Pharmaceutical compositions of microbially produced interleukin-2
CA1337671C (en) Process for recovering purified, oxidized, renatured recombinant interleukin-2 from microorganisms

Legal Events

Date Code Title Description
BB Publication of examined application
PC Transfer of assignment of patent

Owner name: HOECHST MARION ROUSSEL

MM Patent lapsed

Owner name: HOECHST MARION ROUSSEL